Latest Oncology News

Loaiza-Bonilla on Applications, Actionability, and Affordability of AI in Oncology

November 26th 2020

By OncLive Staff

In our exclusive interview, Dr. Loaiza-Bonilla explains how AI can be used to optimize patient care, provides insight into the research that has been done to develop potential applications for AI in oncology, and sheds light on some of the barriers that have to be overcome in order to effectively implement AI in oncology.

Investigators Take Stock of New Landscape for Metastatic HER2-Positive Breast Cancer

November 26th 2020

By Brittany Cote

Breast cancer specialists discuss noteworthy data on efficacy and safety about fam-trastuzumab deruxtecan-nxki, neratinib, and tucatinib.

FDA Approves Naxitamab-gqgk for Relapsed/Refractory High-Risk Neuroblastoma

November 25th 2020

By Gina Mauro

The FDA has approved naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.

Selinexor Improves PFS in Advanced Unresectable Dedifferentiated Liposarcoma

November 25th 2020

By Gina Mauro

Selinexor demonstrated a statistically significant improvement in progression-free survival compared with matching placebo in patients with advanced unresectable dedifferentiated liposarcoma, following at least 2 prior treatments.

Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC

November 25th 2020

By Caroline Seymour

Milind Javle, MD, provides insight into the current treatment paradigm of advanced HCC and the potential influence ongoing research regarding biomarkers of response and novel combinations could have on the field.

Latest Oncology Videos

Dr. Pandalai on the Efficacy of Cytoreductive Surgery Plus HIPEC in Colorectal Peritoneal Carcinomatosis

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Dr. El Chaer on the Potential for Combination Strategies With Ruxolitinib in MPNs

Treatment Options in Myelodysplastic Syndromes

Back to the Future: How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Dr. Choyke on Recent Developments in Imaging for Prostate Cancer

Dr. Kim on Curative Treatment Options in HCC

Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL

Dr. Boutros on the Utility of Genetic Testing in Prostate Cancer

Dr. Opyrchal on the Current State of Biomarkers in TNBC

Dr. Mikhael on Remaining Challenges in High-Risk Multiple Myeloma

Dr. Luke the Role of Molecular Testing in Melanoma

Dr. Mascarenhas on the Significance of Pacritinib in Myelofibrosis

Dr. Ayers on Trials Examining Venetoclax in CLL

Dr. Janjigian on the Importance of First-Line Therapy Selection in Gastric Cancer

Dr. Dorritie on Determining Transplant Eligibility in Multiple Myeloma

Dr. Lin on the Limitations of Current Biomarkers in Prostate Cancer

Dr. Price on the Challenges of the CodeBreaK 100 Trial in GI Cancers

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

Dr. Ruan on Treatment Considerations in MCL

Dr. Eng on Features of High-Risk CRC

Dr. Mascarenhas on Emerging Agents in Myelofibrosis

Dr. Lonial on Unanswered Questions With T-Cell Engagers in Myeloma

All Oncology News

SIENDO Trial of Selinexor in Endometrial Cancer Gets Green Light to Continue

November 25th 2020

By Gina Mauro

The phase 3 SIENDO study, which is evaluating maintenance selinexor in endometrial cancer, has been recommended by the Data and Safety Monitoring Board to continue as previously planned without the need to add additional patients to the trial or amend the study protocol, following a prespecified interim futility analysis.

Ruxolitinib Is Linked With High Spleen Responses in IPSS Low-Risk Myelofibrosis

November 25th 2020

By Hayley Virgil

November 25, 2020 — Ruxolitinib, when administered earlier on in the treatment course, led to high spleen response rates in patients with low-risk International Prognostic Scoring System myelofibrosis.

Idasanutlin Promotes Transient Expansion of TP53-Mutant Subclones in Polycythemia Vera

November 25th 2020

By Jessica Hergert

November 25, 2020 - The oral MDM2 antagonist idasanutlin was found to promote expansion of TP53-mutant subclones among patients with polycythemia vera.

Panelists Parse Out Answers to Key Questions in Hematologic Malignancies

November 25th 2020

By Jessica Hergert

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

November 25th 2020

By Shiruyeh Schokrpur, MD, PHD

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

New Strategies Enhance Care in mUC

November 25th 2020

By Guru P. Sonpavde, MD

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

Nivolumab Approved in Europe for Advanced Esophageal Cancer

November 24th 2020

By Gina Mauro

November 24, 2020 - The European Commission has approved nivolumab for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma following prior fluoropyrimidine- and platinum-based combination chemotherapy.

CAR T-Cell Therapy Creates Opportunities for Individualized Treatment in MCL

November 24th 2020

By Caroline Seymour

Alan P. Z. Skarbnik, MD, highlights how treatment decisions in mantle cell lymphoma have become more nuanced since the FDA approval of the CAR T-cell therapy brexucabtagene autoleucel in the relapsed/refractory setting.

3D Printing Leads to Improved Precision and Reconstruction in Limb Salvage Surgery in Bone Tumors, Soft Tissue Sarcomas

November 24th 2020

By Hayley Virgil

R. Lor Randall, MD, FACS, discusses limb salvage surgeries that have been made possible through 3D printing, and the technological advances that are helping to increase precision and turnaround times.

CAR T-Cell Therapy Transforms Leukemia and Lymphoma Treatment, But Toxicities Concerns Remain

November 24th 2020

By Erica DiNapoli

Olalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.

Devimistat Granted Orphan Drug Status for Soft Tissue Sarcoma

November 24th 2020

By Gina Mauro

November 24, 2020 — The FDA has granted an orphan drug designation to devimistat for the treatment of patients with soft tissue sarcoma.

Treatment Selection Becomes Complex Amid Growing Armamentarium in HER2+ Breast Cancer

November 24th 2020

By Jessica Hergert

Nusayba Bagegni, MD, discusses prominent data that have emerged in early-stage and metastatic HER2-positive breast cancer.

Pexidartinib Demonstrates Long-Term Efficacy, Safety in Tenosynovial Giant Cell Tumors

November 24th 2020

By Kristi Rosa

November 24, 2020 - Pexidartinib was found to result in prolonged efficacy with favorable safety in patients with tenosynovial giant cell tumors, according to long-term data from a pooled analysis of 3 cohorts of patients who received the agent.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

By Jane de Lartigue, PhD

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS

November 23rd 2020

By Gina Mauro

November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.

See All News